The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Age-specific prognostic factors for survival in patients with advanced ovarian cancer (OC) treated with platinum/taxane-based primary chemotherapy: A combined explorative analysis of three prospective phase III trials from the AGO study group.
F. Hilpert
Consultant or Advisory Role - Roche
Honoraria - GlaxoSmithKline; Roche
A. M. Hempel
No relevant relationships to disclose
J. Hedderich
No relevant relationships to disclose
O. Junge
No relevant relationships to disclose
P. Harter
No relevant relationships to disclose
A. Du Bois
Consultant or Advisory Role - Johnson & Johnson; PharmaMar; Roche
Honoraria - GlaxoSmithKline; Roche; Schering-Plough
J. Pfisterer
No relevant relationships to disclose